FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164669103> ?p ?o ?g. }

• W3164669103 endingPage "2001" @default.
• W3164669103 startingPage "1984" @default.
• W3164669103 abstract "Postmastectomy radiation (PMRT) is an important adjuvant treatment for high-risk breast cancer. However, evidence concerning its efficacy in promoting survival of patients with 1-3 positive axillary lymph nodes remains insufficient.We identified 57,793 patients, diagnosed from 2010-2015, from the Surveillance, Epidemiology, and End Results database, including 15,126 cases treated with beam radiation and 42,667 cases with none/unknown radiation. A Kaplan-Meier curve was utilized to compare survival of the two groups. We used univariate and multivariate Cox proportional hazard models to identify independent prognostic factors presented as hazard ratios (HRs) and 95% confidence intervals (CIs). For subgroup analysis, patients were stratified according to lymph node status, tumor size, and molecular subtypes.The PMRT group showed more aggressive clinicopathological features, including higher grades (P<0.001), larger tumor sizes (P<0.001), more lymph nodes (P<0.001), younger ages (P<0.001), more ER-negative cases (P<0.001), more PR-negative cases (P<0.001), and more HER2 overexpression (P<0.001). In addition, the PMRT group received more radical surgeries (P<0.001) and more chemotherapy (P<0.001). In the multivariate Cox proportional hazard regression analysis, the PMRT group exhibited improved survival in terms of breast cancer specific survival (BCSS) (HR, 0.74; 95% CI, 0.68-0.81; P<0.001) and overall survival (OS) (HR, 0.72; 95% CI, 0.67-0.78; P<0.001). After stratification according to positive axillary lymph nodes, the PMRT group showed improved BCSS and OS in the LN 1 to 3 subgroup (HR, 0.74; 95% CI, 0.64-0.85; P<0.001 and HR, 0.68; 95% CI, 0.60-0.78; P<0.001, respectively). For patients with 1-3 positive axillary lymph nodes and T1-2 tumors, the PMRT group still showed improved BCSS and OS (HR, 0.823; 95% CI, 0.69-0.99; P=0.04 and HR, 0.75; 95% CI, 0.64-0.88; P<0.001, respectively). In the subgroup analysis, PMRT remained a significant favorable prognostic factor in T2 and HER2-/HR+ subtype (P<0.05).This study suggests that PMRT can confer a survival benefit to breast cancer patients with 1-3 positive axillary lymph nodes, even with modern treatment options. Furthermore, for patients with 1-3 positive axillary lymph nodes and T1-2 tumors, PMRT can still provide survival benefits." @default.
• W3164669103 created "2021-06-07" @default.
• W3164669103 creator A5002318539 @default.
• W3164669103 creator A5012018493 @default.
• W3164669103 creator A5058395349 @default.
• W3164669103 creator A5059512368 @default.
• W3164669103 creator A5084358857 @default.
• W3164669103 creator A5090189228 @default.
• W3164669103 date "2021-05-01" @default.
• W3164669103 modified "2023-09-23" @default.
• W3164669103 title "Postmastectomy radiation therapy can improve survival for breast cancer patients with 1–3 positive axillary lymph nodes: a retrospective cohort study using the SEER database" @default.
• W3164669103 cites W1266768180 @default.
• W3164669103 cites W1948261638 @default.
• W3164669103 cites W1974963414 @default.
• W3164669103 cites W1993060137 @default.
• W3164669103 cites W2019109147 @default.
• W3164669103 cites W2036934183 @default.
• W3164669103 cites W2044702943 @default.
• W3164669103 cites W2046826982 @default.
• W3164669103 cites W2060051234 @default.
• W3164669103 cites W2060250348 @default.
• W3164669103 cites W2062298610 @default.
• W3164669103 cites W2092950740 @default.
• W3164669103 cites W2097255042 @default.
• W3164669103 cites W2102078552 @default.
• W3164669103 cites W2102296917 @default.
• W3164669103 cites W2110051776 @default.
• W3164669103 cites W2111549782 @default.
• W3164669103 cites W2113953300 @default.
• W3164669103 cites W2117775530 @default.
• W3164669103 cites W2129825983 @default.
• W3164669103 cites W2129856008 @default.
• W3164669103 cites W2130840692 @default.
• W3164669103 cites W2137829275 @default.
• W3164669103 cites W2138652241 @default.
• W3164669103 cites W2140978771 @default.
• W3164669103 cites W2147187257 @default.
• W3164669103 cites W2147833901 @default.
• W3164669103 cites W2158615473 @default.
• W3164669103 cites W2162852953 @default.
• W3164669103 cites W2163910197 @default.
• W3164669103 cites W2168517539 @default.
• W3164669103 cites W2170016090 @default.
• W3164669103 cites W2171015116 @default.
• W3164669103 cites W2259802687 @default.
• W3164669103 cites W2332829713 @default.
• W3164669103 cites W2415787673 @default.
• W3164669103 cites W2560367415 @default.
• W3164669103 doi "https://doi.org/10.21037/tcr-20-3337" @default.
• W3164669103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35116521" @default.
• W3164669103 hasPublicationYear "2021" @default.
• W3164669103 type Work @default.
• W3164669103 sameAs 3164669103 @default.
• W3164669103 citedByCount "0" @default.
• W3164669103 crossrefType "journal-article" @default.
• W3164669103 hasAuthorship W3164669103A5002318539 @default.
• W3164669103 hasAuthorship W3164669103A5012018493 @default.
• W3164669103 hasAuthorship W3164669103A5058395349 @default.
• W3164669103 hasAuthorship W3164669103A5059512368 @default.
• W3164669103 hasAuthorship W3164669103A5084358857 @default.
• W3164669103 hasAuthorship W3164669103A5090189228 @default.
• W3164669103 hasBestOaLocation W31646691031 @default.
• W3164669103 hasConcept C10515644 @default.
• W3164669103 hasConcept C121608353 @default.
• W3164669103 hasConcept C126322002 @default.
• W3164669103 hasConcept C142724271 @default.
• W3164669103 hasConcept C143998085 @default.
• W3164669103 hasConcept C144301174 @default.
• W3164669103 hasConcept C207103383 @default.
• W3164669103 hasConcept C2777649267 @default.
• W3164669103 hasConcept C2779720271 @default.
• W3164669103 hasConcept C2780849966 @default.
• W3164669103 hasConcept C38180746 @default.
• W3164669103 hasConcept C44249647 @default.
• W3164669103 hasConcept C50382708 @default.
• W3164669103 hasConcept C509974204 @default.
• W3164669103 hasConcept C530470458 @default.
• W3164669103 hasConcept C71924100 @default.
• W3164669103 hasConcept C72563966 @default.
• W3164669103 hasConceptScore W3164669103C10515644 @default.
• W3164669103 hasConceptScore W3164669103C121608353 @default.
• W3164669103 hasConceptScore W3164669103C126322002 @default.
• W3164669103 hasConceptScore W3164669103C142724271 @default.
• W3164669103 hasConceptScore W3164669103C143998085 @default.
• W3164669103 hasConceptScore W3164669103C144301174 @default.
• W3164669103 hasConceptScore W3164669103C207103383 @default.
• W3164669103 hasConceptScore W3164669103C2777649267 @default.
• W3164669103 hasConceptScore W3164669103C2779720271 @default.
• W3164669103 hasConceptScore W3164669103C2780849966 @default.
• W3164669103 hasConceptScore W3164669103C38180746 @default.
• W3164669103 hasConceptScore W3164669103C44249647 @default.
• W3164669103 hasConceptScore W3164669103C50382708 @default.
• W3164669103 hasConceptScore W3164669103C509974204 @default.
• W3164669103 hasConceptScore W3164669103C530470458 @default.
• W3164669103 hasConceptScore W3164669103C71924100 @default.
• W3164669103 hasConceptScore W3164669103C72563966 @default.
• W3164669103 hasIssue "5" @default.
• W3164669103 hasLocation W31646691031 @default.

• next